EMEA-002270-PIP04-20
Key facts
| Active substance |
Marzeptacog alfa (activated)
|
| Therapeutic area |
Haematology-Hemostaseology
|
| Decision number |
P/0482/2021
|
| PIP number |
EMEA-002270-PIP04-20
|
| Pharmaceutical form(s) |
Powder for solution for injection
|
| Condition(s) / indication(s) |
Treatment of Haemophilia B
|
| Route(s) of administration |
Subcutaneous use
|
| Contact for public enquiries |
Catalyst Biosciences, Inc.
Email: cdemocko@catbio.com |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|